Skip to main content

Table 2 Influencing baseline factors on medical costs across ILD subtypes

From: Cost drivers in the pharmacological treatment of interstitial lung disease

 

IPF

PF-ILD

Sarcoidosis

Other ILD

surcharge factor [95% CI]

surcharge factor [95% CI]

surcharge factor [95% CI]

surcharge factor [95% CI]

Male

0.06 [0.00–0.22]

1.05 [0.77–1.34]

0.93 [0.84–1.03]

1.67 [1.59–1.76]*

Former/Current smoker

2.47 [2.40–2.55]*

0.41 [0.00–0.83]

0.91 [0.57—–1.25]

0.82 [0.54–1.11]

Age

1.10 [1.09–1.10]*

1.04 [1.03–1.06]*

1.00 [0.99–1.00]

1.03 [1.02–1.04]*

FVC % pred. At baseline

0.91 [0.90–0.92]*

0.99 [0.98–1.00]

0.99 [0.99–0.99]*

0.99 [0.99–1.00]

Disease duration

1.02 [0.89–1.15]

0.90 [0.90–0.91]*

0.95 [0.93–0.97]*

0.91 [0.91–0.91]*

Comorbidity sum score

1.59 [1.49–1.69]*

1.50 [1.41–1.59]*

1.23 [1.19–1.26]*

1.89 [1.80–1.97]*

  1. *p-value < 0.05